Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer

Journal of Clinical Oncology

Volumn 24, Issue 34, 2006, Pages 5408-5413

  Taplin, Mary Ellen ^a   Xie, Wanling ^a   Bubley, Glenn J ^a   Ernstoff, Marc S ^a   Walsh, William ^a   Morganstern, Daniel E ^a   Regan, Meredith M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE; GONADORELIN AGONIST; GOSERELIN; GRANULOCYTE COLONY STIMULATING FACTOR; LITHIUM; PROSTATE SPECIFIC ANTIGEN; WARFARIN; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RELAPSE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG SAFETY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FOLLOW UP; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADJUVANT THERAPY; CLASSIFICATION; CLINICAL TRIAL; DISEASE COURSE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSTATE TUMOR; REMISSION; SALVAGE THERAPY;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; ESTRAMUSTINE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; REMISSION INDUCTION; SALVAGE THERAPY; TAXOIDS;

EID: 34247241577     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.6589     Document Type: Article

References (18)

1. Vargas C, Kestin L, Weed D, et al: Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features. Int J Radiat Oncol Biol Phys 61:714-724, 2005
2. Stephenson A, Shariat S, Zelefsky M, et al: Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291:1325-1332, 2004
3. Stephenson A, Eastham J: Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy. J Clin Oncol 23:8198-8203, 2005
4. Pacholke H, Wajsman Z, Algood C, et al: Postoperative adjuvant and salvage radiotherapy for prostate cancer: Impact on freedom from biochemical relapse and survival. Urology 64:982-986, 2004
5. Bolla M, van Poppel H, Collette L, et al: Postoperative radiotherapy after radical prostatectomy: A randomized controlled trial (EORTC trial 22911). Lancet 366:572-578, 2005
6. Pound C, Partin A, Eisenberger M, et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591-1597, 1999
7. Freedland SJ, Humphreys EB, Mangold LA, et al: Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294:433-439, 2005
8. Zhou P, Chen M, McLeod D, et al: Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol 23:6992-6998, 2005
9. Messing E, Manola J, Sarosdy M, et al: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341:1781-1788, 1999
10. Goldie J: Scientific basis for adjuvant and primary (neoadjuvant) chemotherapy. Semin Oncol 14:1-7, 1987
11. Carlson RW, Brown E, Burnstein HJ, et al: NCCN task force report: Adjuvant therapy breast cancer. J Natl Comprehensive Cancer Network 4:S1-S26, 2006 (suppl 1)
12. Trudeau M, Charbonneau F, Gelmon K, et al: Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol 6:886-898, 2005
13. Tannock I, de Wit R, Berry W, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004
14. Petrylak D, Tangen C, Hussain M, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004
15. Savarese D, Halabi S, Hars V, et al: Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780-Cancer and Leukemia Group B. J Clin Oncol 19: 2509-2516, 2001
16. Hussain A, Dawson N, Amin P, et al: Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer. J Clin Oncol 23:2789-2796, 2005
17. Grossfeld GD, Chaudhary UB, Reese DM, et al: Intermittent androgen deprivation: Update of cycling characteristics in patients without clinically apparent metastatic prostate cancer. Urology 58: 240-245, 2001
18. De La Taille A, Zerbib M, Conquy S, et al: Intermittent androgen suppression in patients with prostate cancer. BJU International 91:18-22, 2003